New Possibilities to Reduce the Residual Risk in Patients with Ischemic Heart Disease

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Stable ischemic heart disease (IHD) patients face persistent high cardiovascular complication rates despite advances.
• A subset of IHD patients with comorbidities and acute events on therapy exhibits higher residual risk.
• Optimal treatment strategies often leave significant residual risk, necessitating further intervention.

Purpose of the Study:

• To discuss the lipid, inflammatory, and thrombotic components of residual risk in IHD.
• To explore pharmaceutical interventions for managing these risk factors.
• To specifically address the thrombotic component in IHD patients with diabetes mellitus.

Main Methods:

• Review of current literature on residual risk in IHD.
• Analysis of pharmacological approaches targeting lipid, inflammatory, and thrombotic pathways.
• Focus on evidence for managing thrombotic risk in diabetic IHD patients.

Main Results:

• Residual risk in IHD is multifactorial, involving lipids, inflammation, and thrombosis.
• Pharmacological interventions can target these components to reduce risk.
• Diabetic IHD patients present unique challenges for thrombotic risk management.

Conclusions:

• Aggressive management of residual risk components is crucial for high-risk IHD patients.
• Targeting lipid, inflammatory, and thrombotic factors offers therapeutic opportunities.
• Specific strategies are needed for pharmaceutical correction of thrombotic risk in diabetic IHD.